Market Overview

Vetr Crowd Slowly Turning Positive On Kite Pharma, Now Rates It A Buy

Related KITE
Gilead Sciences Outlook Brightens; Citi Upgrades
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More

Shares of Kite Pharma Inc (NASDAQ: KITE) have been volatile this year, down 4.7 since January. Over the past three months, however, the stock has recuperated almost 23 percent of its value.

It seems like the Vetr crowd believes the rally will go on a bit further, as evidenced by its average price target of $62.43. This target implies a potential return of roughly 4.75 percent from current valuations.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided to upgrade its rating on shares of Kite Pharma on Tuesday, from 3.0 (Hold) to 3.5 stars (Buy) — out of a possible five-star rating.

It should be noted, however, that only 50 percent of the crowd’s ratings are bullish at the time, meaning that the community is slowly turning positive.

Latest Ratings for KITE

Aug 2017WedbushUpgradesUnderperformNeutral
Aug 2017Canaccord GenuityDowngradesBuyHold
Aug 2017SunTrust Robinson HumphreyDowngradesBuyHold

View More Analyst Ratings for KITE
View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (KITE)

View Comments and Join the Discussion!

Barclays Remains Positive On Cerulean Pharma Despite Failed Renal Cancer Trial

Whole Foods Market Ripe For Small Rebound, Vetr Crowd Says